Semaglutide and belly fat: what the evidence actually shows

You've tried cutting back, but the belly stays put, here's what's happening biologically

Visceral fat is not like the fat just under your skin. It wraps around your liver, pancreas and intestines, and it behaves more like an active organ than passive storage, releasing inflammatory signals and affecting insulin sensitivity in ways that subcutaneous fat simply does not. That is precisely why clinicians and researchers pay close attention to it, and why the question of whether Wegovy helps with belly fat specifically carries real clinical weight.

Semaglutide acts on GLP-1 receptors in the hypothalamus, which regulates hunger, and in the gut, where it slows gastric emptying. The net effect is that most people feel full sooner, stay full longer and eat less without experiencing the gnawing hunger that usually derails conventional diets. Over weeks, that sustained deficit draws on stored energy, and because visceral fat is metabolically busy, it tends to be mobilised alongside fat from other depots.

Body-composition sub-studies from the STEP 1 trial, published in the New England Journal of Medicine, confirmed reductions in total fat mass and waist circumference in the semaglutide group. The average waist reduction was several centimetres, and imaging in related analyses showed visceral fat falling in proportion to overall weight loss. This is not the same as a medicine that selectively dissolves abdominal fat; it is a medicine that produces meaningful total fat loss, and the abdomen tends to reflect that prominently.

What the trial numbers mean for someone starting treatment today

The headline figure from STEP 1 is a roughly 15% average reduction in body weight over 68 weeks at the 2.4mg maintenance dose. For someone weighing 100 kg at the start, that is 15 kg on average, with corresponding reductions in waist circumference typically in the range of 10–14 cm across trial participants. The effect on belly circumference is real, but it reflects the body shrinking overall rather than a laser-focused abdominal effect.

What matters practically is that visceral fat, because of its metabolic activity, tends to respond earlier and more substantially than slower-mobilised subcutaneous fat in some individuals. Clinicians often note that patients report their clothes fitting differently around the waist before the scales show dramatic change, a pattern consistent with what the imaging data suggested.

Individual results depend on how consistently treatment is taken, the dose reached, what a person eats alongside it, and their activity levels. The medicine is prescribed alongside a reduced-calorie diet and increased physical activity; neither component is optional. You can explore whether semaglutide burns belly fat in more depth, but the short answer is: it creates the conditions; the body does the work.

One practical detail patients often ask about: Wegovy injection pens need to be kept in the fridge at 2–8°C. Most people settle into keeping the current pen in the fridge door, which becomes as automatic as reaching for the milk. Storage specifics are in the Patient Information Leaflet that comes with your prescription.

Who can access semaglutide for weight management, and what the NHS says about belly fat

Wegovy is licensed in the UK by the MHRA for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. The NHS semaglutide medicines page sets out what the treatment involves and the common side effects to expect.

On the NHS, Wegovy is currently available through specialist weight management services under NICE guidance, with phased criteria that remain relatively strict. Many people who are clinically eligible find waiting lists long. That gap is where a regulated private service becomes relevant, not as a shortcut past clinical assessment, but as a route that still involves a prescriber reviewing your case before any medicine is dispensed. Our weight loss treatment overview explains how semaglutide sits within a broader clinical approach.

Semaglutide is a prescription-only medicine. A prescriber determines suitability based on your medical history, current medications and circumstances, BMI alone is never the whole picture. Questions about how much belly fat semaglutide removes are best answered by a clinician who can factor in your individual starting point.

What good clinical oversight looks like, and why it matters for this treatment

Because semaglutide reduces appetite substantially, patients sometimes under-eat protein or let hydration slip. Both matter for preserving lean muscle mass, which is what keeps metabolic rate healthy as weight falls. A prescriber and ongoing aftercare exist precisely to catch these patterns, not just to hand over a prescription and disappear.

Gastrointestinal side effects (nausea, loose stools, constipation or some combination) are common early on and after dose increases, and typically settle within a couple of weeks. They are rarely dangerous, but they are more manageable with guidance on eating pace, meal size and what to do if they persist. The January 2026 MHRA Drug Safety Update flagged acute pancreatitis as an infrequent but serious risk across GLP-1 medicines: severe stomach pain radiating to the back warrants urgent medical attention, not a wait-and-see approach.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not automated software. Treatment is dispatched the same day once approved and arrives the next working day via DPD in plain packaging. You can see more about our approach on the about us page or read about what Wegovy costs privately before starting. If you think semaglutide might be right for you, the first step is a free clinical consultation.

Start your free consultation and a prescriber will review your details the same day.